The efficacy and safety of gemtuzumab ozogamicin (CMA-676) in patients with acute myeloid leukemia in first relapse.

被引：0
|
作者：
Voliotis, D
Mineur, P
Dombret, H
Theobald, M
Boogaerts, M
Löwenberg, B
Sievers, EL
Larson, RA
Estey, E
Diehl, V
Stadtmauer, EA
机构：
[1] Univ Cologne, Clin Internal Med 1, Koeln, Germany
[2] Hop St Joseph, Gilly Charleroi, Belgium
[3] Hop St Louis, Paris, France
[4] Univ Clin Mainz, Mainz, Germany
[5] Univ Ziekenhuis Gasthuisberg, Louvain, Belgium
[6] Dijkzigt Ziekenhuis Rotterdam, Rotterdam, Netherlands
[7] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[8] Univ Chicago, Chicago, IL 60637 USA
[9] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[10] Univ Penn, Philadelphia, PA 19104 USA
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
424O
引用
收藏
页码：95 / 95
页数：1
相关论文
共 50 条
  • [1] Update of efficacy and safety of gemtuzumab ozogamicin (Mylotarg®, CMA-676) in patients ≥ 60 years of age with acute myeloid leukemia in first relapse.
    Larson, RA
    Boogaerts, M
    Estey, E
    Karanes, C
    Stadtmauer, EA
    Sievers, EL
    Mineur, P
    Bennett, JM
    Berger, MS
    Eten, CB
    Munteanu, M
    Loken, MR
    van Dongen, JJM
    Bernstein, ID
    Appelbaum, FR
    BLOOD, 2001, 98 (11) : 215B - 215B
  • [2] Remission classification for patients with acute myeloid leukemia in first relapse treated with gemtuzumab ozogamicin (CMA-676).
    Sievers, EL
    Larson, RA
    Estey, E
    Stadtmauer, EA
    Appelbaum, FR
    CLINICAL CANCER RESEARCH, 2000, 6 : 4559S - 4559S
  • [3] Efficacy and safety of CMA-676 in patients with AML in first relapse.
    Sievers, EL
    Larson, RA
    Estey, E
    Stadtmauer, EA
    Erba, HP
    Roy, DCC
    Tarantolo, L
    Spielberger, R
    Berger, MS
    Eten, C
    Manley, L
    Stone, A
    Bernstein, I
    Appelbaum, FR
    BLOOD, 1999, 94 (10) : 696A - 696A
  • [4] Interim analysis of the efficacy and safety of CMA-676 in patients with AML in first relapse.
    Sievers, EL
    Larson, RA
    Estey, E
    Stadtmauer, E
    Berger, M
    Eten, C
    Bernstein, I
    Appelbaum, F
    BLOOD, 1998, 92 (10) : 613A - 613A
  • [5] A final analysis of the efficacy and safety of gemtuzumab ozogamicin in 277 patients with acute myeloid leukemia in first relapse.
    Larson, RA
    Sievers, EL
    Stadtmauer, EA
    Löwenberg, B
    Estey, E
    Dombret, H
    Theobald, M
    Voliotis, D
    Leopold, LH
    Riche, M
    Berger, MS
    Sherman, ML
    Appelbaum, FR
    BLOOD, 2002, 100 (11) : 338A - 338A
  • [6] Gemtuzumab Ozogamicin (CMA-676, Mylotarg) for the treatment of CD33+ acute myeloid leukemia
    Voutsadakis, IA
    ANTI-CANCER DRUGS, 2002, 13 (07) : 685 - 692
  • [7] A decision analysis of expected cost savings with outpatient administration of gemtuzumab ozogamicin (Mylotarg™, CMA-676) in patients in first relapse of acute myeloid leukemia (AML).
    Mallick, R
    Sievers, E
    Berger, M
    BLOOD, 2000, 96 (11) : 439A - 439A
  • [8] Preliminary report of an ascending dose study of gemtuzumab ozogamicin (Mylotarg™, CMA-676) in pediatric patients with acute myeloid leukemia.
    Sievers, EL
    Arceci, R
    Franklin, J
    Lange, B
    Shannon, K
    Smith, F
    Berger, MS
    Eten, C
    Auen, M
    BLOOD, 2000, 96 (11) : 217B - 217B
  • [9] Prolonged disease-free survival in patients with acute myeloid leukemia in first relapse treated with gemtuzumab ozogamicin (Mylotarg™, CMA-676) followed by hematopoietic stem cell transplantation.
    Sievers, EL
    Larson, RA
    Estey, E
    Lowenberg, B
    Erba, HP
    Gramatzki, M
    List, A
    Sierra, J
    Stadtmauer, EA
    Tarantolo, S
    Berger, MS
    Leopold, LH
    Eten, C
    Munteanu, M
    Stone, A
    Bernstein, ID
    Appelbaum, FR
    BLOOD, 2000, 96 (11) : 320A - 320A
  • [10] Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse
    Sievers, EL
    Larson, RA
    Stadtmauer, EA
    Estey, E
    Löwenberg, B
    Dombret, H
    Karanes, C
    Theobald, M
    Bennett, JM
    Sherman, ML
    Berger, MS
    Eten, CB
    Loken, MR
    van Dongen, JJM
    Bernstein, ID
    Appelbaum, FR
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (13) : 3244 - 3254
12345